Needham initiated coverage on Axsome Therapeutics with a new price target
$AXSM
Biotechnology: Pharmaceutical Preparations
Health Care
Needham initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $130.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2025 | $179.00 | Buy | B. Riley Securities |
| 9/3/2025 | $163.00 | Overweight | Wells Fargo |
| 7/3/2025 | $190.00 | Overweight | Morgan Stanley |
| 6/3/2025 | $185.00 | Outperform | Oppenheimer |
| 4/7/2025 | $200.00 | Buy | Jefferies |
| 2/11/2025 | $176.00 | Buy | Deutsche Bank |
| 12/31/2024 | $124.00 → $122.00 | Outperform | Mizuho |
| 9/3/2024 | $140.00 | Overweight | Wells Fargo |
4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is recognizing Mental Illness Awareness Week (MIAW) alongside the national mental health advocacy community including the National Alliance on Mental Illness (NAMI). This year's theme for MIAW is "Building Community: Supporting Mental Well-being Together," to highlight the importance of meaningful connections, the value of grassroots advocacy, and impact of local action to strengthen mental health support within communities. "Mental health matters every day. But during MIAW, we come
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, November 3, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presenta
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced six presentations across its broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2025, being held September 17 - 21, 2025, in San Diego, California. Details of the presentations are as follows: Major Depressive Disorder Title: Initiating Auvelity® (dextromethorphan 45 mg-bupropion 105 mg) in Patients with Major Depressive Disorder: Expert Panel Consensus RecommendationsPresentation Date and Time: Friday, September 19, 1:30 - 3:00 p.m. and 6:0
4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)
B. Riley Securities initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $179.00
Wells Fargo resumed coverage of Axsome Therapeutics with a rating of Overweight and set a new price target of $163.00
Morgan Stanley resumed coverage of Axsome Therapeutics with a rating of Overweight and set a new price target of $190.00
144 - Axsome Therapeutics, Inc. (0001579428) (Subject)
144 - Axsome Therapeutics, Inc. (0001579428) (Subject)
144 - Axsome Therapeutics, Inc. (0001579428) (Subject)
Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) investors that a lawsuit filed on behalf of investors that purchased Axsome securities between May 10, 2021 and April 22, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome's board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice President of Eli Lilly and Company and President of Lilly Oncology, where under her leadership, the business unit evolved from one to five marketed medicines. At Lilly, she held leadership position
SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)
SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)
SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, November 3, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presenta
Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI® 2Q 2025 net product revenue of $30.0 million, representing growth of 35% year-over-year and 19% sequentially SYMBRAVO® launched June 10th, with 2Q 2025 net product sales of $0.4 million AUVELITY® market access expanded by 28 million new covered lives in the commercial channel First group purchasing organization (GPO) contract for SYMBRAVO® signed Supplemental NDA submission for AXS-05 in Alzheimer's disease agit
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentat